Short Bowel Syndrome Is Not a Contraindication for Kidney Transplantation

• Published in: Pediatric transplantation 2024-12, Vol.28 (8), p.e14889-n/a
• Main Authors: Tastemel Ozturk, Tugba, Gulhan, Bora, Gumus, Ersin, Hizarcioglu‐Gulsen, Hayriye, Kurt‐Sukur, Eda Didem, Bozaci, Ali Cansu, Aki, Fazil Tuncay, Duzova, Ali, Topaloglu, Rezan, Ozaltin, Fatih
• Format: Article
• Language: English
• Subjects: autosomal recessive polycystic kidney disease; Dehydration; Diarrhea; Drug dependence; Graft rejection; Humans; Immunosuppression; Immunosuppressive agents; Immunosuppressive Agents - therapeutic use; Infant; Intestinal Volvulus - complications; Intestinal Volvulus - etiology; Intestinal Volvulus - surgery; Kidney diseases; Kidney Transplantation; Kidney transplants; Male; Mycophenolate mofetil; Mycophenolic acid; Mycophenolic Acid - therapeutic use; Parenteral nutrition; Patients; Pediatrics; Polycystic kidney; Polycystic Kidney, Autosomal Recessive - complications; Polycystic Kidney, Autosomal Recessive - surgery; Prednisolone; Prednisolone - therapeutic use; Short bowel syndrome; Short Bowel Syndrome - complications; Short Bowel Syndrome - surgery; Small intestine transplantation; Tacrolimus; Tacrolimus - therapeutic use; Treatment Outcome
• ISSN: 1397-3142; 1399-3046; 1399-3046
• DOI: 10.1111/petr.14889

ABSTRACT Background Short bowel syndrome (SBS) is a malabsorptive condition that develops as a result of massive resection of the small intestine and causes morbidities such as chronic diarrhea, dehydration attacks, parenteral nutrition (PN) dependence, and recurrent infections. Kidney transplantation in this patient group may be complicated by aforementioned morbidities, as well as the absorption problems of immunosuppressive drugs. Methods We report the first pediatric patient (18‐month‐old male) with SBS secondary to volvulus who underwent a successful living related kidney transplantation with a primary diagnosis of autosomal recessive polycystic kidney disease and had a successful 4‐year follow‐up without intestinal transplantation. Results Tacrolimus, mycophenolate mofetil (MMF), and prednisolone were administered for maintenance of immunosuppression after transplantation. The patient reached therapeutic trough levels of tacrolimus with usual doses. The 4‐year renal survival was excellent without a clinical evidence of rejection, despite long‐term necessity of PN and intravenous fluids. Conclusions Kidney transplantation should not be avoided in patients with SBS solely because of concerns about the effectiveness of immunosuppressive therapy. Prednisolone, tacrolimus, and MMF combination was effective in our case, and these drugs can be considered as first‐line agents in these patients.